Following yesterday’s news that the US Food and Drug administration had granted breakthrough status to acalabrutinib, London-listed AstraZeneca (LSE: AZN) has announced the drug has also been accepted for priority review by the American regulator.
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor that has undergone a Phase II clinical trial in relapsed/refractory mantle cell lymphoma (MCL).
The company says it will present results from the clinical trial at a forthcoming medical meeting. A decision from the US FDA is now expected in the first quarter of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze